Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Clin Genitourin Cancer. 2021 Mar 19;19(5):405–416. doi: 10.1016/j.clgc.2021.03.011

Fig. 2. [18F]-BF3-Cy3-ACUPA PET/CT imaging of Patient 1 with disseminated PCa.

Fig. 2

Patient 1 had undergone RP and was receiving adjuvant luteinizing hormone-releasing hormone (LHRH) analog therapy prior to this study. Patient 1 also had a hip replacement surgery prior to this study. The patient’s serum PSA was 199 μg/L. A) Coronal and B) Sagittal whole-body PET (red)/CT (grey) MIP images show general and focal [18F]-BF3-Cy3-ACUPA distribution. Specific PCa lesions (“a–d”) are indicated by magenta arrows. C) CT only (inverted, grey) and D) [18F]-BF3-Cy3-ACUPA PET (red)/CT (inverted, grey) transverse cross-sections show specific PCa lesions (indicated by magenta markings).